Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

Neural Stem Cell Transplantation Shows Promise for ... Chromosomal Chaos Promotes Therapy Resistance in Leukemia Cells and Opens Up New Treatment Approaches Nov. 25, 2024 — Chromosomal ...

The future is bright for our bone marrow transplant program,” Dr. Hana Safah said. "We look forward to advancing blood cancer ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis ...

Minot State University, along with MSU Athletics and the Beaver football program have partnered with NMDP for a drive.

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

Why Children With Down Syndrome Have Higher Risk of Leukemia Sep. 26 ... made a world first breakthrough into creating blood stem cells that closely resemble those in the human body.

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.